Verastem Oncology (VSTM)
8.20
+0.22 (2.76%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC
August 14, 2026 10:30 AM - SEC Filing
Verastem (VSTM) PT Lowered to $13 at Mizuho
August 11, 2026 6:35 AM - StreetInsider
Form SCHEDULE 13G Verastem, Inc. Filed by: STATE STREET CORP
August 7, 2026 11:11 AM - SEC Filing
Form 8-K Verastem, Inc. For: Aug 06
August 7, 2026 6:21 AM - SEC Filing
Form 8-K Verastem, Inc. For: Aug 06
August 6, 2026 4:35 PM - SEC Filing
Verastem Oncology (VSTM) Tops Q2 EPS by 12c
August 6, 2026 4:21 PM - StreetInsider
Form 10-Q Verastem, Inc. For: Jun 30
August 6, 2026 4:18 PM - SEC Filing
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
August 6, 2026 4:01 PM - BizWire
Form 4 Verastem, Inc. For: Aug 03 Filed by: Paterson Dan
August 5, 2026 4:37 PM - SEC Filing
Form SCHEDULE 13G Verastem, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:46 AM - SEC Filing
Form SCHEDULE 13G/A Verastem, Inc. Filed by: BlackRock, Inc.
July 30, 2026 11:20 AM - SEC Filing
Verastem doses first patient in colorectal cancer trial for VS-7375
July 28, 2026 4:01 PM - StreetInsider
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
July 28, 2026 4:01 PM - BizWire
Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
July 23, 2026 4:33 PM - SEC Filing
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026 7:30 AM - BizWire
Verastem doses first patient in lung cancer trial for VS-7375
July 22, 2026 4:01 PM - StreetInsider
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
July 22, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A Verastem, Inc. Filed by: Polar Capital Holdings Plc
July 8, 2026 9:49 AM - SEC Filing
Verastem (VSTM) PT Lowered to $14 at RBC Capital
July 7, 2026 8:00 AM - StreetInsider
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026 4:30 PM - BizWire
Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
June 25, 2026 4:02 PM - SEC Filing
Form 4 Verastem, Inc. For: Jun 22 Filed by: Paterson Dan
June 24, 2026 4:45 PM - SEC Filing
Form 4 Verastem, Inc. For: Jun 22 Filed by: Calkins Daniel
June 24, 2026 4:45 PM - SEC Filing
RBC Capital on Verastem (VSTM): 'We think shares are undervalued'
June 24, 2026 9:37 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
June 24, 2026 6:45 AM - StreetInsider
BTIG Reiterates Buy Rating on Verastem (VSTM)
June 24, 2026 3:18 AM - StreetInsider
Form 8-K Verastem, Inc. For: Jun 23
June 23, 2026 4:03 PM - SEC Filing
Verastem reports early trial data for KRAS G12D cancer drug VS-7375
June 23, 2026 4:01 PM - StreetInsider
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
June 23, 2026 4:01 PM - BizWire
Form 144 Verastem, Inc. Filed by: Paterson Dan
June 22, 2026 7:51 PM - SEC Filing
Mizuho Reiterates Outperform Rating on Verastem (VSTM), maintain "June top pick"
June 18, 2026 6:36 AM - StreetInsider
Form 8-K Verastem, Inc. For: Jun 16
June 17, 2026 8:52 AM - SEC Filing
Verastem reports 86% six-month survival rate in pancreatic cancer trial
June 17, 2026 7:31 AM - StreetInsider
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
June 17, 2026 7:30 AM - BizWire
VERASTEM doses first patient in Phase 2 pancreatic cancer trial
June 16, 2026 4:01 PM - StreetInsider
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
June 16, 2026 4:01 PM - BizWire
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
June 15, 2026 4:01 PM - BizWire
Buy this biotech stock now, Mizuho urges
June 9, 2026 2:00 PM - StreetInsider
Full Article List
